PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10449621-7	1999	Successful rejection was achieved with folate conjugates of Fab or scFv fragments.	Folic Acid	39-45	FA complementation group B	Homo sapiens	60-63	
32329959-5	2020	In proof-of-concept studies, this cp-Fab/CAR-T system targeting folate binding sites in the cell surfaceome mediated potent and specific eradication of folate receptor-expressing cancer cells in vitro and in vivo .	Folic Acid	64-70	FA complementation group B	Homo sapiens	37-40	
32028640-5	2020	Given the systemic toxicity of l-BSO, we developed a new formulation using polyurea (PURE) dendrimers nanoparticles (l-BSO@PUREG4-FA2), targeting l-BSO delivery in a folate functionalized nanoparticle.	Folic Acid	166-172	FA complementation group B	Homo sapiens	130-133	
31461931-5	2019	In this study, l-BSO was encapsulated in a folate-targeted generation four polyurea dendrimer (PUREG4-FA2) and its release profile was followed for 24 h at pH 7.4 and 37  C. The protocol uses in situ l-BSO derivatization, by the formation of a catechol-derived orto-quinone, followed by visible detection of the derivative at 503 nm.	Folic Acid	43-49	FA complementation group B	Homo sapiens	95-105	
25514347-9	2015	Folate competition assays showed that PME-(PEG3.4k-FA2)1.72 complexes had stronger targeting ability than PME-(PEG3.5k)1.69 and PME-(PEG3.4k-FA1)1.66 complexes due to their higher folate density per PEG molecule.	Folic Acid	0-6	FA complementation group B	Homo sapiens	51-54	
25514347-9	2015	Folate competition assays showed that PME-(PEG3.4k-FA2)1.72 complexes had stronger targeting ability than PME-(PEG3.5k)1.69 and PME-(PEG3.4k-FA1)1.66 complexes due to their higher folate density per PEG molecule.	Folic Acid	180-186	FA complementation group B	Homo sapiens	51-54	
25514347-11	2015	Distribution and uptake in 3D multicellular spheroid assays showed that divalent folate could offer PME-(PEG3.4k-FA2)1.72 complexes stronger penetrating ability and higher cellular uptake.	Folic Acid	81-87	FA complementation group B	Homo sapiens	113-116	
9267842-6	1997	In an alternative approach to the generation of a targeted adenoviral vector, we conjugated folate to the neutralising Fab fragment of an anti-fibre monoclonal antibody.	Folic Acid	92-98	FA complementation group B	Homo sapiens	119-122	
9634824-5	1996	Therefore, we conjugated folate to the neutralizing Fab fragment of an anti-fiber monoclonal antibody.	Folic Acid	25-31	FA complementation group B	Homo sapiens	52-55